Vertex Pharmaceuticals Incorporated (VRTX) announced the FDA has granted Fast Track Designation for VX-880. VX-880, formerly known as STx-02, is an investigational allogeneic human stem cell-derived islet cell therapy that is being evaluated for patients who have type 1 diabetes with impaired hypoglycemic awareness and severe hypoglycemia.

Create Account

Dark

chart

exchange

Check out our Level2View

Vertex Pharmaceuticals Incorporated (VRTX) announced the FDA has granted Fast Track Designation for VX-880. VX-880, formerly known as STx-02, is an investigational allogeneic human stem cell-derived islet cell therapy that is being evaluated for patients who have type 1 diabetes with impaired hypoglycemic awareness and severe hypoglycemia.

RTTNews | Mar 10, 2021 08:08AM EST

08:07 Wednesday, March 10, 2021 (RTTNews.com) - Vertex Pharmaceuticals Incorporated (VRTX) announced the FDA has granted Fast Track Designation for VX-880. VX-880, formerly known as STx-02, is an investigational allogeneic human stem cell-derived islet cell therapy that is being evaluated for patients who have type 1 diabetes with impaired hypoglycemic awareness and severe hypoglycemia.

The company has started a clinical trial for VX-880 in patients who have type 1 diabetes with severe hypoglycemia and impaired hypoglycemic awareness. The clinical trial is a phase 1/2, single-arm, open-label study. Approximately 17 patients will be enrolled in the trial.

Read the original article on RTTNews ( https://www.rttnews.com/3176358/vertex-reports-fda-fast-track-designation-for-vx-880-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved